Compounds > vatalanib
Page last updated: 2024-09-04

vatalanib and Myelodysplastic Syndromes

vatalanib has been researched along with Myelodysplastic Syndromes in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bloomfield, CD; Gupta, P; Hasserjian, RP; Hurd, DD; Larson, RA; Mulkey, F; Odenike, OM; Owzar, K; Sanford, BL; Stone, RM; Vij, R1
Gupta, P; Hurd, D; Larson, RA; Lewis, LD; Miller, AA; Mulkey, F; Murry, DJ; Owzar, K; Ratain, MJ; Vij, R; Wang, X1
Bilic, S; Carlin, R; Cortes, JE; Feldman, EJ; Giles, FJ; Kowalski, M; Laurent, D; List, AF; Masson, E; Roboz, GJ; Rosamilia, M; Schuster, MW1

Trials

3 trial(s) available for vatalanib and Myelodysplastic Syndromes

ArticleYear
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome

2013
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
    British journal of clinical pharmacology, 2014, Volume: 78, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Computer Simulation; Data Interpretation, Statistical; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Phthalazines; Prospective Studies; Pyridines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Young Adult

2014
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Leukemia, 2006, Volume: 20, Issue:6

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2

2006